235 related articles for article (PubMed ID: 33201284)
1. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.
Muglia R; Simonelli M; Pessina F; Morenghi E; Navarria P; Persico P; Lorenzi E; Dipasquale A; Grimaldi M; Scorsetti M; Santoro A; Politi LS
Eur Radiol; 2021 Jun; 31(6):4079-4086. PubMed ID: 33201284
[TBL] [Abstract][Full Text] [Related]
2. The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective.
Sütcüoğlu O; Erdal ZS; Akdoğan O; Çeltikçi E; Özdemir N; Özet A; Uçar M; Yazıcı O
Turk J Med Sci; 2023 Feb; 53(1):413-419. PubMed ID: 36945944
[TBL] [Abstract][Full Text] [Related]
3. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
Furtner J; Genbrugge E; Gorlia T; Bendszus M; Nowosielski M; Golfinopoulos V; Weller M; van den Bent MJ; Wick W; Preusser M
Neuro Oncol; 2019 Dec; 21(12):1587-1594. PubMed ID: 31369680
[TBL] [Abstract][Full Text] [Related]
4. A novel radiographic marker of sarcopenia with prognostic value in glioblastoma.
Huq S; Khalafallah AM; Ruiz-Cardozo MA; Botros D; Oliveira LAP; Dux H; White T; Jimenez AE; Gujar SK; Sair HI; Pillai JJ; Mukherjee D
Clin Neurol Neurosurg; 2021 Aug; 207():106782. PubMed ID: 34186275
[TBL] [Abstract][Full Text] [Related]
5. Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.
Ten Cate C; Huijs SMH; Willemsen ACH; Pasmans RCOS; Eekers DBP; Zegers CML; Ackermans L; Beckervordersandforth J; van Raak EPM; Anten MHME; Hoeben A; Postma AA; Broen MPG
J Neurooncol; 2022 Dec; 160(3):611-618. PubMed ID: 36394717
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
7. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.
Furtner J; Berghoff AS; Albtoush OM; Woitek R; Asenbaum U; Prayer D; Widhalm G; Gatterbauer B; Dieckmann K; Birner P; Aretin B; Bartsch R; Zielinski CC; Schöpf V; Preusser M
Eur Radiol; 2017 Aug; 27(8):3167-3173. PubMed ID: 28050694
[TBL] [Abstract][Full Text] [Related]
8. Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials.
Furtner J; Weller M; Weber M; Gorlia T; Nabors B; Reardon DA; Tonn JC; Stupp R; Preusser M;
Clin Cancer Res; 2022 Jan; 28(1):129-136. PubMed ID: 34667022
[TBL] [Abstract][Full Text] [Related]
9. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
An G; Ahn S; Park JS; Jeun SS; Hong YK
J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
[TBL] [Abstract][Full Text] [Related]
10. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?
Yesil Cinkir H; Colakoglu Er H
Asia Pac J Clin Oncol; 2020 Oct; 16(5):e223-e227. PubMed ID: 32762134
[TBL] [Abstract][Full Text] [Related]
11. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
12. Temporal muscle thickness as an independent prognostic marker in glioblastoma patients-a systematic review and meta-analysis.
Sadhwani N; Aggarwal A; Mishra A; Garg K
Neurosurg Rev; 2022 Dec; 45(6):3619-3628. PubMed ID: 36350492
[TBL] [Abstract][Full Text] [Related]
13. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
15. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of temporal muscle thickness, a novel radiographic marker of sarcopenia, in patients with brain tumor: A systematic review and meta-analysis.
Yang YW; Ming Yang ; Zhou YW; Xia X; Jia SL; Zhao YL; Zhou LX; Cao Y; Ge ML
Nutrition; 2023 Aug; 112():112077. PubMed ID: 37236042
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
18. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.
Furtner J; Berghoff AS; Schöpf V; Reumann R; Pascher B; Woitek R; Asenbaum U; Pelster S; Leitner J; Widhalm G; Gatterbauer B; Dieckmann K; Höller C; Prayer D; Preusser M
J Neurooncol; 2018 Oct; 140(1):173-178. PubMed ID: 30008154
[TBL] [Abstract][Full Text] [Related]
19. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]